101ST GENERAL ASSEMBLY
State of Illinois
2019 and 2020
SB3659
 
Introduced 2/14/2020, by Sen. Melinda Bush
 
SYNOPSIS AS INTRODUCED:
 

 
720 ILCS 570/322 new

     Amends the Illinois Controlled Substances Act. Provides that a prescriber shall offer a prescription for naloxone hydrochloride, or another similar drug approved by the Food and Drug Administration, under specified circumstances. Provides for educational information to be provided concerning overdose prevention and the use of naloxone hydrochloride. Provides that a prescriber who does not comply with specified requirements shall be subject to administrative sanctions under the appropriate licensing board. Specifies that the provisions do not create a private right of action against a prescriber, and do not limit a prescriber's liability for the negligent failure to diagnose or treat a patient.
  


LRB101 18151 RLC 67592 b

 
 
A BILL FOR
 

  
SB3659LRB101 18151 RLC 67592 b


  
1    AN ACT concerning criminal law.
  
 
2    Be it enacted by the People of the State of Illinois,
 
3represented in the General Assembly:
  
 
 
4    Section 5. The Illinois Controlled Substances Act is 
5amended  by adding Section 322 as follows:
 
6    (720 ILCS 570/322 new)
7    Sec. 322. Naloxone hydrochloride prescription.
8    (a)   Notwithstanding any provision of law to the contrary, a 
9prescriber shall:
10        (1) offer a prescription for naloxone hydrochloride or 
11    another drug approved by the United States Food and Drug 
12    Administration for the complete or partial reversal of 
13    opioid depression to a patient when one or more of the 
14    following conditions are met:
15            (i) the prescription dosage for the patient is 90 
16        or more morphine milligram equivalents of an opioid 
17        medication per day;
18            (ii) an opioid medication is prescribed 
19        concurrently with a prescription for benzodiazepine; 
20        or
21            (iii) the patient presents with an increased risk 
22        for overdose, including a patient with a history of 
23        overdose, a patient with a history of substance use 
 
 
SB3659- 2 -LRB101 18151 RLC 67592 b

1        disorder, or a patient at risk for returning to a high 
2        dose of opioid medication to which the patient is no 
3        longer tolerant;
4        (2) consistent with the existing standard of care, 
5    provide education to patients receiving a prescription 
6    under paragraph (1) of this subsection (a) on overdose 
7    prevention and the use of naloxone hydrochloride or another 
8    drug approved by the United States Food and Drug 
9    Administration for the complete or partial reversal of 
10    opioid depression; and
11        (3) consistent with the existing standard of care, 
12    provide education on overdose prevention and the use of 
13    naloxone hydrochloride or another drug approved by the 
14    United States Food and Drug Administration for the complete 
15    or partial reversal of opioid depression to one or more 
16    persons designated by the patient, or, for a patient who is 
17    a minor, to the minor's parent or guardian.
18    (b)   A prescriber who does not comply with the requirements 
19of this Section shall be subject to administrative sanctions 
20under the appropriate licensing board. This Section does not 
21create a private right of action against a prescriber, and does 
22not limit a prescriber's liability for the negligent failure to 
23diagnose or treat a patient.